Bio-Rad and Allegheny Health Network Cancer Institute collaborate to advance personalised monitoring of solid tumor cancers with Droplet Digital PCR
Collaboration aims to grow clinical evidence supporting the use of Bio-Rad’s ddPCR™ technology for molecular residual disease monitoring of patients across a range of solid tumor types.
Bio-Rad launches first Ultrasensitive Multiplexed Digital PCR Assay for breast cancer mutation detection in clinical research
Highly Sensitive and Multiplexed Assay for the Detection, Discrimination, and Quantification of Key Mutations in ESR1 Gene for Breast Cancer, Developed for Bio-Rad’s QX600™ Droplet Digital™ PCR System
Key Charpentier/Doudna CRISPR patent upheld by China National Intellectual Property Administration
Dublin, Ireland : ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual prop
Bio-Rad launches validated antibodies for rare cell and circulating tumor cell enumeration
Antibodies validated for use with Bio-Rad’s Celselect Slides™ enumeration stain kits to enable immunostaining of captured circulating tumor cells in liquid biopsy samples.
Teva UK and Closed Loop Medicine announce strategic partnership to advance development of personalised medicines
Castleford and London: Teva UK Limited and Closed Loop Medicine Ltd have announced a strategic partnership to advance the development of personalised medicine.
Ubiquigent and Debiopharm Enter Agreement to Support USP1 Inhibitor Programme for Debio 0432
Project will be a demonstration of how Ubiquigent’s DUB-centric platform can support the development of DUB inhibitors all the way from discovery through to clinical development.
ArgusEye introduces AugaOne to accelerate downstream bioprocess development
AugaOne sensor system provides specific, real-time, and automated data to reduce mAb process development time
Arrayjet’s ArrayPlex platform selected by Immunome for use in its discovery of targeted cancer therapies
Arrayjet’s patented spot-on-spot microarray screening technology is available for customers to adopt in-house and via Arrayjet’s CRO/CMO services Immunome signs deal to use Arrayjet platform in its in-house scree
Ricoh and ERS Genomics enter into CRISPR/Cas9 license agreement
CRISPR/Cas9 genome editing technology contributes to the expansion of the creation of novel disease model
Exploristics and Exonate announce successful collaboration to enhance clinical trial study design using cloud-based simulation
Exploristics’ cloud-based simulation platform KerusCloud used to enhance study design for Exonate’s upcoming Phase IIb study following successful Phase Ib/IIa study
Metrion Biosciences strengthens team with three key appointments
Clare Rutty promoted to CFO, Sue Peffer appointed Head of Marketing, Leanne Clarke appointed HR Officer.
Ubiquigent enters agreement with Astellas subsidiary, Nanna Therapeutics
Agreement leverages Ubiquigent’s DUB-focused drug discovery platform to support the development of novel therapeutic candidates for multiple disease targets selected by Nanna Therapeutics
Exonate first-in-class eye drop Phase Ib/IIa trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema
EXN407 is the first topical SRPK1 inhibitor to demonstrate both safety and signals of biological response as monotherapy for these indications Data generated fully
SolasCure publishes Phase IIa Clinical Trial Report in leading Wound Care Journal
Publication in the ‘International Wound Journal’ provides robust validation of the Phase IIa trial data that will enable further clinical studies Study demonstrates proof-of-
Bio-Rad launches Vericheck ddPCR Replication Competent Lentivirus and Replication Competent AAV Kits for cell and gene therapy production
Rapid, Sensitive, and Validated Detection of Viral Replication Genes Using Droplet Digital™ PCR During Cell and Gene Therapy Production
MIP Discovery closes £7M Series A financing to drive commercialization in cell and gene therapy space
Company’s synthetic affinity reagents are antibody alternatives designed to advance the speed, safety, and efficiency of manufacturing at scale, making advanced therapies more accessible to patient
Closed Loop Medicine demonstrates application of novel drug plus software product for personalized treatment of hypertension
Study published in JAHA validates use of proprietary technology to identify personalized dose regimen, leading to improved blood pressure control and exceptionally high adherence in hypertension patients
Yokogawa introduces CellVoyager High-Content Analysis System CQ3000
New system enables advanced analysis of live cell cultures with high-definition, high-speed 3D imaging
Enhanc3D Genomics appoints Dr Daniel Turner as Chief Scientific Officer
Appointment forms part of ongoing plans for continued development of the GenLink3D genomics platform and formation of strategic commercial and academic partnerships
CN Bio appoints Joseph Parisi as US Director of Sales to support accelerated growth in key OOC market
Cambridge, UK, 30 January 2024: CN Bio, a leading Organ-on-a-Chip (OOC) company that designs
Enterprise Therapeutics Closes £26 million ($33.1 million) Series B Follow-on Financing
Round led by new investor Panakes, with participation from all existing investors
Asimov launches LV Edge Packaging System to optimize lentivirus production
Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced the launch of their LV Edge Packaging System, which improves the cost efficiency and reduces the supply chain risk of lentiviral production.
PlaqueTec and the Babraham Institute collaborate on phenotypic screen of coronary artery blood
Collaboration to develop a bespoke cell phenotyping assay for human blood Project aims to investigate cell types present in coronary artery samples from patients with CAD participating in PlaqueTec’s BIOPATTERN trial
Calluna Pharma launches and announces EUR 75 million Series A financing to develop novel therapies for inflammatory and fibrotic diseases
· Clinical stage company formed from the merger of Oxitope Pharma and Arxx Therapeutics
ERS Genomics and StemSight sign CRISPR/Cas9 license agreement
License agreement provides StemSight access to CRISPR/Cas9 technology to be applied in development of cell therapies for corneal blindness